MedPath

A Study Evaluating the Clinical Efficacy of Treatment based on Chinese Medicine Guideline in Patients With Myasthenia Gravis

Phase 1
Conditions
Myasthenia gravis
Registration Number
ITMCTR2100005025
Lead Sponsor
The Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1.Age is not limited, gender is not limited;
2.Clinical MG manifestations, and or neostigmine test positive, low frequency repeated electrical stimulation positive, serum AChR, Musk, LRP4, Titin, RyR and other antibodies are positive, clinical diagnosis of myasthenia gravis can be diagnosed;
3.Patients with myasthenia gravis classified as type I, type II (type IIa, type IIb), III (type IIIa, type IIIb) and IV (type IVa, IVb) in clinical MGFA;
4.Agree to participate in this study and sign an informed consent form.

Exclusion Criteria

1.Patients with severe medical diseases: severe arrhythmia, severe lung disease, ALT/AST> 2 times the normal value, Cr> 2 times the normal value;
2.Patients with malignant tumors (excluding thymoma), history of HIV infection, or severe immunodeficiency;
3.Female patients who are pregnant, breastfeeding or breastfeeding;
4.History of mental illness;
5.Tuberculosis patients with tuberculin test or T-SPOT test positive.

Study & Design

Study Type
Observational study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quantitative myasthenia gravis score;
Secondary Outcome Measures
NameTimeMethod
Security Index;Myasthenia gravis specific muscle strength test;Analysis of the dosage of other drugs such as cholinesterase inhibitors, glucocorticoids, immunosuppressants, etc.;Myasthenia Gravis Daily Living Scale;Acetylcholine receptor antibody quantitative value;Absolute and relative scores for myasthenia gravis;Myasthenia Gravis Quality of Life Scale;
© Copyright 2025. All Rights Reserved by MedPath